A study of 947 endometrial carcinomas from patients with early-stage disease originally included in the PORTEC-1 and PORTEC-2 trials was classified according to the four major molecular subtypes: p53-mutant tumors, microsatellite instable tumors, POLE-mutant tumors, and tumors of a non-specific molecular profile. This evidence concerns the gene TP53 and endometrial carcinoma.